Zai Lab Secures Inclusion of Six Medicines in 2025 NRDL
Written by Emily J. Thompson, Senior Investment Analyst
Source: Businesswire
Updated: 4 hour ago0mins
- NRDL Update: Zai Lab's VYVGART, NUZYRA, and ZEJULA have successfully been renewed for inclusion in the 2025 National Reimbursement Drug List (NRDL), reflecting the company's strong clinical value and significantly reducing the financial burden on patients.
- Increased Product Diversity: This update brings Zai Lab's total products in the NRDL to six, enhancing the company's competitive edge in the Chinese market and better addressing the demand for high-quality novel medicines among patients.
- Accelerated Market Access: By including these innovative drugs in the NRDL, Zai Lab not only improves patient accessibility but also potentially increases market share through enhanced treatment outcomes, driving future revenue growth.
- Commitment to Innovation: Zai Lab emphasizes its ongoing commitment to enhancing the accessibility and affordability of its medicines, ensuring that more patients can benefit from innovative therapies as early as possible, which underscores the company's long-term dedication to the Chinese healthcare market.
ZLAB.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on ZLAB
Wall Street analysts forecast ZLAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZLAB is 53.73 USD with a low forecast of 25.70 USD and a high forecast of 74.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.950
Low
25.70
Averages
53.73
High
74.00
Current: 19.950
Low
25.70
Averages
53.73
High
74.00
Goldman Sachs
downgrade
2025-11-03
Reason
Goldman Sachs
Price Target
2025-11-03
downgrade
Reason
Goldman Sachs analysts removed Zai Lab from the firm's APAC Conviction List as part of its monthly update.
Citi
Buy
maintain
$66 -> $69
2025-08-11
Reason
Citi
Price Target
$66 -> $69
2025-08-11
maintain
Buy
Reason
Citi raised the firm's price target on Zai Lab to $69 from $66 and keeps a Buy rating on the shares. The firm updated the company's model post the Q2 report.
Cantor Fitzgerald
Li Watsek
Buy
Reiterates
n/a
2025-03-27
Reason
Cantor Fitzgerald
Li Watsek
Price Target
n/a
2025-03-27
Reiterates
Buy
Reason
JP Morgan
Anupam Rama
Buy
Maintains
$44 → $51
2025-03-13
Reason
JP Morgan
Anupam Rama
Price Target
$44 → $51
2025-03-13
Maintains
Buy
Reason
JPMorgan raised the firm's price target on Zai Lab to $51 from $44 and keeps an Overweight rating on the shares. The firm updated models in the small-cap biotechnology space.
See All Ratings
About ZLAB
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the implications of Edmondson's share sale for Zai Lab?
Why did Edmondson choose to sell 14,328 shares on November 21, 2025?
How might Edmondson's share sale impact Zai Lab's stock performance in the future?
Will other executives at Zai Lab follow Edmondson's decision to sell shares?